Ependymoma

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
7 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Platinum compound 1 substance
Alkylating agent 1 substance
Topoisomerase II inhibitor 1 substance
Antimetabolite 1 substance
Vinca alkaloid 1 substance
Phase II/III: 1 Phase I/II: 1 Phase I: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II/III

1 trial
  • Centre Leon Berard Academic
    CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; METHOTREXATE; SODIUM VALPROATE; VINCRISTINE SULFATE
    2024-512222-28-00 13 countries 2015 n=894
    Recruiting

Phase I/II

1 trial
  • Centre Oscar Lambret Academic
    IMP not specified
    2024-513470-22-00 1 country 2019 n=63
    Ended

Phase I

1 trial
  • Prinses Maxima Centrum voor Kinderoncologie B.V. Academic
    4-((2,4-DIFLUOROPHENYL)METHYL)2,4,6,7,8,9-HEXAHYDRO-7(PHENYLMETHYL)IMIDAZO(1,2-A)PYRIDO(3,4-E)PYRIMIDIN-5(1H)-ONE
    2025-521180-13-00 1 country 2026 n=20
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Prinses Maxima Centrum voor Kinderoncologie B.V. Academic 1 Phase I 1
Centre Leon Berard Academic 1 Phase II/III 1
Centre Oscar Lambret Academic 1 Phase I/II 0
New trials by year
2019
1
2026
1
← All indication landscapes